Korean J Ophthalmol.  2017 Dec;31(6):574-575. 10.3341/kjo.2017.0100.

Management of Anterior Chamber Migration of Dexamethasone Intravitreal Implant

• Ha JY
• Jang JY
• Ji YS

• KMID: 2396711
• DOI: http://doi.org/10.3341/kjo.2017.0100

Abstract

No abstract available.

MeSH Terms

Anterior Chamber*
Dexamethasone*
Dexamethasone

Figure

• 

  Fig. 1 Case 1. (A) Anterior segment photograph demonstrates migration of the intravitreal dexamethasone implant into the anterior chamber with mild corneal edema 8 days after injection. (B) Fundus photograph shows the implant in the vitreous cavity after repositioning through ocular massage in the supine position. (C) Anterior segment photograph demonstrates improved corneal edema 4 days after repositioning. Case 2. (D) Anterior segment photograph demonstrates migration of the intravitreal dexamethasone implant into the anterior chamber with severe corneal edema 4 days after injection. (E) In the operating field, the implant was removed from the anterior chamber with a microforceps. There was no fragmentation of the implant during the procedure. (F) Anterior segment photograph demonstrates improved corneal edema.

Reference

1. Rahimy E, Khurana RN. Anterior segment migration of dexamethasone implant: risk factors, complications, and management. Curr Opin Ophthalmol. 2017; 28:246–251.

2. Pacella F, Agostinelli E, Carlesimo SC, et al. Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report. J Med Case Rep. 2016; 10:282.

3. Bansal R, Bansal P, Kulkarni P, et al. Wandering Ozurdex(®) implant. J Ophthalmic Inflamm Infect. 2012; 2:1–5.

4. Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology. 2014; 121:67–71.